Overview

Location [1]
11p15.5
Pathway
MAP kinase signaling
Protein [2]
GTPase HRas, N-terminally processed
Synonyms [1]
C-BAS/HAS, C-H-RAS, CTLO, RASH1, HRAS1, H-RASIDX, p21ras, C-HA-RAS1, HAMSV

HRAS (Harvey rat sarcoma viral oncogene homolog) encodes the GTPase HRas protein, one of three human RAS proteins. RAS proteins are small GTPases that are central mediators downstream of growth factor receptor signaling and therefore critical for cell proliferation, survival, and differentiation. HRAS is implicated in the pathogenesis of several cancers.

 

HRAS is altered in 0.97% of all cancers with bladder urothelial carcinoma, myelodysplastic syndromes, breast invasive ductal carcinoma, acute myeloid leukemia, and lung adenocarcinoma having the greatest prevalence of alterations [3].

HRAS GENIE Cases - Top Diseases

The most common alterations in HRAS are HRAS Mutation (1.32%), HRAS Missense (1.08%), HRAS Codon 61 Missense (0.34%), HRAS Q22Pfs*26 (0.19%), and HRAS Codon 13 Missense (0.18%) [3].

HRAS GENIE Cases - Top Alterations

Significance of HRAS in Diseases

Malignant Solid Tumor +

Colorectal Carcinoma +

Non-Small Cell Lung Carcinoma +

Myelodysplastic Syndromes +

Acute Myeloid Leukemia +

Non-Hodgkin Lymphoma +

Melanoma +

Glioma +

Chronic Myelomonocytic Leukemia +

Multiple Myeloma +

Squamous Cell Lung Carcinoma +

Poorly Differentiated Thyroid Gland Carcinoma +

Cancer +

Acute Lymphoblastic Leukemia +

Head And Neck Squamous Cell Carcinoma +

Histiocytic And Dendritic Cell Neoplasm +

Neuroblastoma +

Neurofibromatosis Type 1 +

Ovarian Carcinoma +

Pancreatic Carcinoma +

Pancreatic Ductal Adenocarcinoma +

Small Cell Lung Carcinoma +

Thyroid Gland Follicular Carcinoma +

Malignant Thyroid Gland Neoplasm +

Thyroid Gland Carcinoma +

Thyroid Gland Adenocarcinoma +

Urothelial Carcinoma +

Thyroid Gland Papillary Carcinoma +

Rhabdomyosarcoma +

Squamous Cell Carcinoma +

Soft Tissue Sarcoma +

Endometrial Carcinoma +

Prostate Carcinoma +

Colorectal Adenocarcinoma +

Breast Carcinoma +

Chronic Myeloid Leukemia +

Diffuse Large B-Cell Lymphoma +

Double-Hit Lymphoma +

Hepatocellular Carcinoma +

Low Grade Ovarian Serous Adenocarcinoma +

Malignant Peripheral Nerve Sheath Tumor +

Mantle Cell Lymphoma +

Peripheral T-Cell Lymphoma +

Renal Cell Carcinoma +

Rhabdoid Tumor +

Schwannoma +

Secondary Acute Myeloid Leukemia +

Therapy-Related Acute Myeloid Leukemia +

Thymic Carcinoma +

Thyroid Gland Undifferentiated (Anaplastic) Carcinoma +

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.